Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers

Wyeth Pharmaceuticals, a division of Wyeth , announced today that it has submitted a Biologic License Application (BLA) to the U.S. FDA for Prevnar 13(TM), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein).

The details can be read here.